^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Focus V (anlotinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO Asia 2022
    Title:

    386P - Efficacy of anlotinib in posterior line treatment of locally advanced and metastatic NSCLC with KRAS mutation

    Published date:
    11/28/2022
    Excerpt:
    This study aims to observe and evaluate the clinical efficacy, safety and prognostic factors of anlotinib versus traditional chemotherapy for locally advanced and metastatic NSCLC with KRAS mutation that failed in first-line treatment...anlotinib was superior to the traditional chemotherapy in terms of ORR, DCR, mPFS with less toxicity and better safety.
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Manag Res
    Title:

    Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway

    Published date:
    05/19/2020
    Excerpt:
    Anlotinib inhibited proliferation of KRAS mutant lung cancer cells and induced apoptosis in vitro.
    DOI:
    10.2147/CMAR.S243660